Managed by Globewerks International for the Singapore Society of Oncology.

SSO-CIC Symposium. SPEAKERS

Ibrahim Ramy.png

Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as chief medical officer and vice president of clinical development at the Parker Institute for Cancer Immunotherapy.

Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.

Parker Institute for Cancer Immunotherapy

Ramy IBRAHIM

Prof Lee Soo Chin - For Website.jpg

The major focus of Dr Lee Soo Chin’s laboratory is to study pharmacogenetics and genomics in breast cancer. Using the neoadjuvant model, she has completed several clinical studies with collection of biological samples, including germline DNA, tumor and plasma, and conducted immunohistochemistry, genomic and proteomic studies to understand chemotherapy effects and to identify predictive markers of treatment response. She has also studied the pharmacogenetics of several commonly used chemotherapeutic agents in breast cancer, including doxorubicin, docetaxel and gemcitabine, and identified candidate gene variants that influence treatment toxicity and outcome. In addition, she has an interest in understanding inter-ethnic differences in drug outcomes between Asians and Caucasians and between different Asian races, and has studied the pharmacogenetics of warfarin and doxorubicin in relation to this. The goal of her research is to establish algorithms comprising key clinical and genetic predictors for optimal selection of anti-cancer drug for the individual patient.

National University Cancer Institute

LEE Soo Chin

Toh-Han-Chong.jpg

Dr Toh is Senior Consultant and former Head at the Department of Medical Oncology and now Deputy Director, National Cancer Centre, Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is also alumni at the Harvard Business School. He is currently the vice-chairman of the Oncology Academic Clinical Program (ACP) for Education.

National Cancer Centre Singapore

TOH Han Chong

30419_edited.jpg

Dr David Tan is a consultant medical oncologist and clinician scientist at the National University Cancer Institute, Singapore.  His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents. 

In addition to his clinical and academic duties, he is currently also the Associate Chairman Medical Board for Research at the National University Hospital, Singapore and Head of the Innovation Transfer Office at National University Health Systems (NUHS).  He is also a member of the Novel Agents Committee for Cancer (NACC) at the Experimental Therapeutics Centre in A*STAR Singapore. 

National University Cancer Institute, Singapore

David TAN